FilingsTodayBcworldpharm
At a glance
Bcworldpharm filed 32 disclosures in the last 12 months, including 6 insider and 5 5% holder. The most recent key filing was on Aug 4.
Revenue for 2025 was ₩75.8B, up 1.3% on 2024. Operating margin was 2.6% against 2% a year earlier. Debt was 144% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩40.8B and operating profit of ₩2B.
The 2025 annual report lists 288 employees with an average tenure of 5.2 years and average pay of ₩40.7M, #1737 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩175.4M each on average. It paid ₩100 per common share in cash dividends, against ₩100 a year earlier (+0%). 홍성한 and related parties held 38.92% at year end.
From the 2025 annual report
Staff: 288 (152 men, 136 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩11.7B. Directors and auditors: 6, paid ₩1.1B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩100 | ₩100 | ₩100 |
| Payout ratio | -29.6% | -16.4% | 18.8% |
| Yield (as filed) | 1.80% | 2.10% | 1.50% |
| Total cash dividends | ₩929M | ₩543M | ₩543M |
Largest shareholder
홍성한 holds 20.16%; with 5 related parties the group holds 38.92% of common shares at year end (from 38.74% at the start of the year).
Auditor: 삼정회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.